Details of the Drug

General Information of Drug (ID: DMFJH5Q)

• Drug Name: Mephentermine
• Synonyms: Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane

Indication

Disease Entry	ICD 11	Status	REF
High blood pressure	BA00	Approved	[1]

• Therapeutic Class: Vasoconstrictor Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  C01CA11: Mephentermine
  C01CA: Adrenergic and dopaminergic agents
  C01C: CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
  C01: CARDIAC THERAPY
  C: CARDIOVASCULAR SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 163.26
  Logarithm of the Partition Coefficient (xlogp); 2.4
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 1
• ADMET Property:
  Half-life: The concentration or amount of drug in body reduced by one-half in 17 - 18 hours [2]
  Metabolism: The drug is metabolized via the hepatic []
• Chemical Identifiers:
  Formula: C11H17N
  IUPAC Name: N,2-dimethyl-1-phenylpropan-2-amine
  Canonical SMILES: CC(C)(CC1=CC=CC=C1)NC
  InChI: InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
  InChIKey: RXQCGGRTAILOIN-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3677
  ChEBI ID: CHEBI:6755
  CAS Number: 100-92-5
  UNII: TEZ91L71V4
  DrugBank ID: DB01365
  TTD ID: D0G1OZ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[3]

Molecular Expression Atlas of This Drug

• The Studied Disease: High blood pressure
• ICD Disease Classification: BA00

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mephentermine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Increased risk of hyperpyrexia by the combination of Mephentermine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[4]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Mephentermine and Droxidopa.	Autonomic nervous system disorder [8D87]	[5]
Levomilnacipran	DMV26S8	Moderate	Increased risk of rapid heart rate by the combination of Mephentermine and Levomilnacipran.	Chronic pain [MG30]	[6]
Milnacipran	DMBFE74	Moderate	Additive hypertensive effects by the combination of Mephentermine and Milnacipran.	Depression [6A70-6A7Z]	[6]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of rapid heart rate by the combination of Mephentermine and Desvenlafaxine.	Depression [6A70-6A7Z]	[6]
Ozanimod	DMT6AM2	Moderate	Increased risk of hyperpyrexia by the combination of Mephentermine and Ozanimod.	Multiple sclerosis [8A40]	[4]
Safinamide	DM0YWJC	Moderate	Decreased metabolism of Mephentermine caused by Safinamide mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[7]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Mephentermine and Rasagiline.	Parkinsonism [8A00]	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [3] Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.
• [4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [5] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [6] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".